Trial Profile
A retrospective, cohort study to compare the incidence of bleeding related hospitalisation and 30 day rehospitalisation in patients with nonvalvular atrial fibrillation treated with Dabigatran or Warfarin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2017
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Embolism and thrombosis
- Focus Therapeutic Use
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 24 May 2017 New trial record